Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2024-12-20 Capital/Financing Update
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience AB announces outcome of exercise of warrants series TO 9
Capital/Financing Update Classification · 1% confidence The document is a press release titled "ALLIGATOR BIOSCIENCE AB ANNOUNCES OUTCOME OF EXERCISE OF WARRANTS SERIES TO 9". It details the results of a warrant exercise, including the number of shares subscribed, the resulting capital increase, and the dilution effect. This type of announcement, which concerns changes to the company's capital structure resulting from financing activities (warrant exercise), fits best under the 'Capital/Financing Update' category. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it is a specific announcement about capital structure changes due to financing, 'CAP' is the most appropriate code. It is not a general regulatory filing (RNS) because a more specific category exists.
2024-12-20 English
Alligator Bioscience AB meddelar utfall för nyttjandet av teckningsoptioner serie TO 9
Capital/Financing Update Classification · 1% confidence The document is a press release titled "ALLIGATOR BIOSCIENCE AB MEDDELAR UTFALL FÖR NYTTJANDET AV TECKNINGSOPTIONER SERIE TO 9" (Alligator Bioscience AB announces outcome for the exercise of warrants series TO 9). It details the results of a warrant exercise, including the number of warrants utilized, the resulting share issuance, the capital raised (approx. 0.8 MSEK), and the resulting change in the total number of shares and share capital. This concerns a specific corporate action related to capital structure and financing activities, specifically the conversion of warrants into shares. This aligns best with the 'Capital/Financing Update' category (CAP). Although it relates to shares, it is not a general share issue announcement (SHA) but the result of a pre-existing financing instrument (warrants). It is not a full financial report (10-K, IR) or a general regulatory filing (RNS), but a specific announcement about capital structure change resulting from a financing event.
2024-12-20 Swedish
Last day of trading in warrants series TO 9 in Alligator Bioscience AB is 13 December 2024
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the last day of trading for a specific series of warrants (TO 9) related to a prior rights issue. It details the exercise period, subscription price, issue volume, and resulting share capital changes/dilution. This type of announcement, which concerns capital structure changes, financing instruments (warrants), and share issuance implications, fits best under the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific corporate action related to financing instruments.
2024-12-13 English
Sista dag för handel med teckningsoptioner serie TO 9 i Alligator Bioscience AB är den 13 december 2024
Share Issue/Capital Change Classification · 1% confidence The document is a press release written in Swedish concerning the final trading day for warrants (teckningsoptioner serie TO 9) related to a previous rights issue. It details the terms of the warrants, the exercise period, the subscription price, and the resulting capital increase and dilution upon full exercise. This type of announcement, which relates to the mechanics of capital structure changes (specifically the expiration/exercise of warrants issued during a financing event), fits best under 'Capital/Financing Update' (CAP). It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it pertains specifically to a capital event.
2024-12-13 Swedish
Alligator Bioscience publicerar finansiell kalender för 2025
Report Publication Announcement Classification · 1% confidence The document is a press release from Alligator Bioscience announcing their financial calendar for the upcoming year (2025). It lists dates for future reports and meetings but does not contain the actual financial reports or meeting materials themselves. According to the 'Menu vs Meal' rule, an announcement regarding the timing or publication of future reports is classified as a Report Publication Announcement (RPA).
2024-12-04 Swedish
Alligator Bioscience publishes financial calendar for 2025
Report Publication Announcement Classification · 1% confidence The document is a short press release (under 5,000 characters) announcing the company's financial calendar for the upcoming year (2025). It does not contain the actual financial reports themselves, but rather provides a schedule of when those reports will be published. According to the 'Menu vs Meal' rule, an announcement regarding the timing or release of future reports is classified as a Report Publication Announcement (RPA).
2024-12-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.